Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014).

Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, Navaneethan SD, Ramanathan V.

Am J Nephrol. 2018;48(6):472-481. doi: 10.1159/000495081. Epub 2018 Nov 23.

PMID:
30472701
2.

Did Medicaid Expansion Reduce Mortality Among Patients Initiating Dialysis for Irreversible Kidney Failure?

Erickson KF, Ho V, Winkelmayer WC.

JAMA. 2018 Dec 4;320(21):2206-2208. doi: 10.1001/jama.2018.14291. No abstract available.

PMID:
30422240
3.

Evaluating the Evidence behind Policy Mandates in US Dialysis Care.

Erickson KF, Winkelmayer WC.

J Am Soc Nephrol. 2018 Dec;29(12):2777-2779. doi: 10.1681/ASN.2018090905. Epub 2018 Nov 2. No abstract available.

PMID:
30389727
4.

Health Insurance in the First 3 Months of Hemodialysis and Early Vascular Access.

Lin E, Mell MW, Winkelmayer WC, Erickson KF.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1866-1875. doi: 10.2215/CJN.06660518. Epub 2018 Nov 1.

PMID:
30385594
5.

Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System.

Brady BM, Zhao B, Niu J, Winkelmayer WC, Milstein A, Chertow GM, Erickson KF.

JAMA Intern Med. 2018 Oct 1;178(10):1358-1367. doi: 10.1001/jamainternmed.2018.3756.

PMID:
30208398
6.

Making Policy in the Dark: The Use of Activated Vitamin D Under Bundled Payments for Dialysis Care.

Awan AA, Thomas SS, Erickson KF.

Am J Kidney Dis. 2018 Aug;72(2):161-163. doi: 10.1053/j.ajkd.2018.04.011. No abstract available.

PMID:
30037474
7.

The Role of Big Data in the Development and Evaluation of US Dialysis Care.

Erickson KF, Qureshi S, Winkelmayer WC.

Am J Kidney Dis. 2018 Oct;72(4):560-568. doi: 10.1053/j.ajkd.2018.04.007. Epub 2018 Jun 18.

PMID:
29921451
8.

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.

Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, Kanwal F.

J Viral Hepat. 2018 Nov;25(11):1270-1279. doi: 10.1111/jvh.12937. Epub 2018 Jul 3.

PMID:
29851265
9.

Market Competition and Health Outcomes in Hemodialysis.

Erickson KF, Zheng Y, Ho V, Winkelmayer WC, Bhattacharya J, Chertow GM.

Health Serv Res. 2018 Oct;53(5):3680-3703. doi: 10.1111/1475-6773.12835. Epub 2018 Feb 22.

PMID:
29468675
10.

Employment among Patients Starting Dialysis in the United States.

Erickson KF, Zhao B, Ho V, Winkelmayer WC.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):265-273. doi: 10.2215/CJN.06470617. Epub 2018 Jan 18.

PMID:
29348264
11.

Health Insurance and the Use of Peritoneal Dialysis in the United States.

Perez JJ, Zhao B, Qureshi S, Winkelmayer WC, Erickson KF.

Am J Kidney Dis. 2018 Apr;71(4):479-487. doi: 10.1053/j.ajkd.2017.09.024. Epub 2017 Dec 23.

PMID:
29277511
12.

A Case for More Frequent, Not Just Earlier, Nephrology Care of Patients Approaching ESRD?

Qureshi S, Erickson KF, Winkelmayer WC.

Am J Kidney Dis. 2017 Aug;70(2):155-157. doi: 10.1053/j.ajkd.2017.04.016. No abstract available.

PMID:
28739124
13.

Home Alone: Does Modality Matter? Revisiting Hospital Readmissions in Dialysis.

Shen JI, Dave NN, Erickson KF.

Am J Kidney Dis. 2017 Jul;70(1):1-3. doi: 10.1053/j.ajkd.2017.04.006. No abstract available.

PMID:
28646981
14.

Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Am J Kidney Dis. 2017 Feb;69(2):237-246. doi: 10.1053/j.ajkd.2016.08.033. Epub 2016 Nov 14.

15.

Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition.

Erickson KF, Zheng Y, Winkelmayer WC, Ho V, Bhattacharya J, Chertow GM.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):536-545. doi: 10.2215/CJN.06340616. Epub 2016 Nov 9.

16.

Effects of physician payment reform on provision of home dialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Am J Manag Care. 2016 Jun 1;22(6):e215-23.

17.

Federal Funding for Kidney Disease Research: A Missed Opportunity.

Mendu ML, Erickson KF, Hostetter TH, Winkelmayer WC, Olan G, Meyer RN, Hakim R, Sedor JR.

Am J Public Health. 2016 Mar;106(3):406-7. doi: 10.2105/AJPH.2015.303009. No abstract available.

18.

A Cost Analysis of Tolerance Induction for Two-Haplotype Match Kidney Transplant Recipients.

Erickson KF, Winkelmayer WC, Busque S, Lowsky R, Scandling JD, Strober S.

Am J Transplant. 2016 Jan;16(1):371-3. doi: 10.1111/ajt.13530. Epub 2015 Nov 9. No abstract available.

19.

Measuring comorbidity in patients receiving dialysis: can we do better?

O'Shaughnessy MM, Erickson KF.

Am J Kidney Dis. 2015 Nov;66(5):731-4. doi: 10.1053/j.ajkd.2015.07.001. Epub 2015 Jul 23. No abstract available.

PMID:
26210068
20.

Overlooked care transitions: an opportunity to reduce acute care use in ESRD.

Erickson KF, Kurella Tamura M.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):347-9. doi: 10.2215/CJN.00220115. Epub 2015 Feb 3. No abstract available.

21.

Provider visit frequency and vascular access interventions in hemodialysis.

Erickson KF, Mell MW, Winkelmayer WC, Chertow GM, Bhattacharya J.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):269-77. doi: 10.2215/CJN.05540614. Epub 2015 Jan 13.

22.

Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis.

Erickson KF, Mell M, Winkelmayer WC, Chertow GM, Bhattacharya J.

J Am Soc Nephrol. 2015 Aug;26(8):1990-7. doi: 10.1681/ASN.2014050464. Epub 2014 Dec 1.

23.

Physician visits and 30-day hospital readmissions in patients receiving hemodialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

J Am Soc Nephrol. 2014 Sep;25(9):2079-87. doi: 10.1681/ASN.2013080879. Epub 2014 May 8.

24.

Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients.

Shen JI, Montez-Rath ME, Mitani AA, Erickson KF, Winkelmayer WC.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):515-25. doi: 10.1002/pds.3595. Epub 2014 Feb 18.

25.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Jan 21;160(2):143. doi: 10.7326/L14-5001-7. No abstract available.

26.

Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Forum Health Econ Policy. 2014 Jan 1;17(1):53-77.

27.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004.

28.

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD.

J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8.

29.

Variation in nephrologist visits to patients on hemodialysis across dialysis facilities and geographic locations.

Erickson KF, Tan KB, Winkelmayer WC, Chertow GM, Bhattacharya J.

Clin J Am Soc Nephrol. 2013 Jun;8(6):987-94. doi: 10.2215/CJN.10171012. Epub 2013 Feb 21.

30.

Interaction between GFR and risk factors for morbidity and mortality in African Americans with CKD.

Erickson KF, Lea J, McClellan WM.

Clin J Am Soc Nephrol. 2013 Jan;8(1):75-81. doi: 10.2215/CJN.03340412. Epub 2012 Oct 18.

31.

The challenges of cost-effectiveness analyses for the clinician.

Erickson KF, Winkelmayer WC.

Am J Kidney Dis. 2010 Dec;56(6):1023-5. doi: 10.1053/j.ajkd.2010.10.001. No abstract available.

Supplemental Content

Loading ...
Support Center